OBJECTIVES: The aim of the study was to assess the extent to which misoprostol alters mucosal or systemic immune responses following either buccal or vaginal administration. METHODS: This was a prospective, crossover pilot study of 15 healthy, reproductive-age women. Women first received 800 μg misoprostol either via buccal or vaginal administration and were crossed over 1 month later to receive the drug via the other route. Cervicovaginal lavage samples, cervical Cytobrush samples, cervicovaginal swabs, urine and blood were obtained immediately prior to drug administration and the following day. Parameters assessed included urine and cervicovaginal misoprostol levels, whole blood cytokine responses (by ELISA) to immune stimulation with lipopolysaccharide, peripheral blood and cervical lymphocyte phenotyping by flow cytometry, cervicovaginal antimicrobial peptide measurement by ELISA and vaginal microbial ecology assessment by 16S rRNA sequencing. RESULTS: Neither buccal nor vaginal misoprostol significantly altered local or systemic immune and microbiological parameters. CONCLUSION: In this pilot study, we did not observe significant alteration of mucosal or systemic immunology or vaginal microbial ecology 1 day after drug administration following either the buccal or vaginal route.
OBJECTIVES: The aim of the study was to assess the extent to which misoprostol alters mucosal or systemic immune responses following either buccal or vaginal administration. METHODS: This was a prospective, crossover pilot study of 15 healthy, reproductive-age women. Women first received 800 μg misoprostol either via buccal or vaginal administration and were crossed over 1 month later to receive the drug via the other route. Cervicovaginal lavage samples, cervical Cytobrush samples, cervicovaginal swabs, urine and blood were obtained immediately prior to drug administration and the following day. Parameters assessed included urine and cervicovaginal misoprostol levels, whole blood cytokine responses (by ELISA) to immune stimulation with lipopolysaccharide, peripheral blood and cervical lymphocyte phenotyping by flow cytometry, cervicovaginal antimicrobial peptide measurement by ELISA and vaginal microbial ecology assessment by 16S rRNA sequencing. RESULTS: Neither buccal nor vaginal misoprostol significantly altered local or systemic immune and microbiological parameters. CONCLUSION: In this pilot study, we did not observe significant alteration of mucosal or systemic immunology or vaginal microbial ecology 1 day after drug administration following either the buccal or vaginal route.
Authors: T Z DeSantis; P Hugenholtz; N Larsen; M Rojas; E L Brodie; K Keller; T Huber; D Dalevi; P Hu; G L Andersen Journal: Appl Environ Microbiol Date: 2006-07 Impact factor: 4.792
Authors: David M Aronoff; Yibai Hao; Jooho Chung; Nicole Coleman; Casey Lewis; Camila M Peres; Carlos H Serezani; Gwo-Hsiao Chen; Nicolas Flamand; Thomas G Brock; Marc Peters-Golden Journal: J Immunol Date: 2008-06-15 Impact factor: 5.422
Authors: Shehzad M Iqbal; Terry B Ball; Pauline Levinson; Lillian Maranan; Walter Jaoko; Charles Wachihi; Brian J Pak; Vladimir N Podust; Kristina Broliden; Taha Hirbod; Rupert Kaul; Francis A Plummer Journal: AIDS Date: 2009-08-24 Impact factor: 4.177
Authors: Kelly S Swanson; Scot E Dowd; Jan S Suchodolski; Ingmar S Middelbos; Brittany M Vester; Kathleen A Barry; Karen E Nelson; Manolito Torralba; Bernard Henrissat; Pedro M Coutinho; Isaac K O Cann; Bryan A White; George C Fahey Journal: ISME J Date: 2010-10-21 Impact factor: 10.302
Authors: A Murat Eren; Marcela Zozaya; Christopher M Taylor; Scot E Dowd; David H Martin; Michael J Ferris Journal: PLoS One Date: 2011-10-25 Impact factor: 3.240
Authors: Johanna Raffetseder; Robert Lindau; Sigrid van der Veen; Göran Berg; Marie Larsson; Jan Ernerudh Journal: Front Immunol Date: 2021-08-09 Impact factor: 7.561